ZIM Laboratories Q2 FY27 Earnings Presentation
Zim Laboratories Ltd · Investor Presentation · 05 Nov 2026, 2:11 am
ZIM Laboratories Q2 FY27 Earnings Presentation ZIM Laboratories reported total operating income of ₹1,054 Mn in Q2 FY27, up 18.9% YoY and 12.0% QoQ, led by RoW formulations. Export revenue grew 24.7% YoY to ₹908 Mn, representing 86% of sales. EBITDA stood at ₹77 Mn with margins at 7.3% (-149 bps YoY), compressed by developed-market readiness costs and EU-GMP CAPA remediation expenses (~₹180 Mn over 15 months). Net loss was ₹21 Mn due to higher depreciation and finance costs. Australia TGA GMP approval was secured, while EU-GMP re-certification remains on track.
Original exchange filing (PDF)
More announcements from Zim Laboratories Ltd
- Transcript of Q2 & H1FY27 Earnings Conference Call · 12 Nov 2026
- Please find enclosed the disclosure pertaining to the audio recording of Q2 & H1 FY27 Earnings Conference Call. · 05 Nov 2026
- Please find enclosed the financial results for the quarter and half year ended 30th September 2026 · 04 Nov 2026
- Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today, .... · 04 Nov 2026
- Zim Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 04 Nov 2026
- We wish to inform you that Q2 & H1FY27 Earnings Conference Call is scheduled to be held on Thursday, 05th November, 2026 at 11:00 a.m. IST. · 31 Oct 2026
- ZIM Laboratories Limited has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 04 Nov 2026
- Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve the Unaudited Financial Results .... · 04 Nov 2026
